

Table 4.27

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	69,788	99.7%	55,680	99.7%	6,974	99.6%	6,009	99.8%	185	100.0%	6,075	99.8%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^f	58,818	84.0%	46,439	83.2%	6,074	86.8%	5,471	90.9%	154	83.2%	5,172	85.0%
Cribriform carcinoma <i>in situ</i> (8201/2)	5,743	8.2%	4,477	8.0%	578	8.3%	587	9.8%	23	12.4%	551	9.1%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	4,094	5.8%	3,369	6.0%	323	4.6%	350	5.8%	-	-	329	5.4%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	23,106	33.0%	18,534	33.2%	2,403	34.3%	1,839	30.6%	59	31.9%	1,904	31.3%
Comedocarcinoma <i>in situ</i> (8501/2)	5,142	7.3%	4,108	7.4%	537	7.7%	429	7.1%	-	-	471	7.7%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,142	1.6%	799	1.4%	191	2.7%	122	2.0%	-	-	110	1.8%
Noninfiltrating intracystic carcinoma(8504/2)	323	0.5%	213	0.4%	48	0.7%	56	0.9%	-	-	28	0.5%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,629	2.3%	1,300	2.3%	190	2.7%	113	1.9%	-	-	140	2.3%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	17,444	24.9%	13,482	24.1%	1,788	25.5%	1,955	32.5%	30	16.2%	1,617	26.6%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	7,953	11.4%	6,783	12.1%	597	8.5%	329	5.5%	20	10.8%	649	10.7%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	7,927	11.3%	6,760	12.1%	594	8.5%	329	5.5%	20	10.8%	649	10.7%
Lobular CIS ^f with other CIS ^f (8524/2)	25	0.0%	23	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,500	3.6%	2,068	3.7%	234	3.3%	160	2.7%	-	-	218	3.6%
Other adenocarcinomas ^g	505	0.7%	379	0.7%	69	1.0%	48	0.8%	-	-	36	0.6%
Other <i>in situ</i> histologies ^h	209	0.3%	167	0.3%	27	0.4%	-	-	-	-	-	-
Total	69,997	100.0%	55,847	100.0%	7,001	100.0%	6,019	100.0%	185	100.0%	6,088	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^f CIS = Carcinoma *in situ*.

^g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.